S100A9 and myelodysplastic syndrome: Transgenic mice expressing S100A9 (S100A9Tg) mimic the features of human MDS, which could be reversed by depletion of MDSCs or by using short hairpin RNA-based (shRNA) silencing of the CD33 receptor, thereby inhibiting the TLR signaling cascade [40].